Assertio Holdings (Nasdaq: ASRT) and Garda Therapeutics announced mutual agreement to postpone the commencement of their previously disclosed tender offer, without specifying a revised timeline or completion date. The transaction, announced in prior filings as a $54 million all-cash acquisition of Garda's specialty pain-management portfolio, had been expected to close in the first half of 2025. Neither party disclosed the cause for delay in the joint statement issued Wednesday.

The postponement follows Assertio's December 2024 announcement that it would acquire Garda to consolidate overlapping specialty pharmaceutical franchises in chronic pain and neurology. Garda's portfolio includes branded and generic analgesic assets targeting central nervous system disorders, a category Assertio has built through prior acquisitions of Zembrace and Indocin. The tender offer mechanism—rather than a straight stock-or-cash deal—suggested Assertio sought direct shareholder participation, a structure typically employed when target management seeks leverage or when debt covenants require bondholder consent. The absence of a revised commencement date indicates unresolved terms, likely tied to financing conditions, regulatory pre-clearance under Hart-Scott-Rodino, or renegotiation of earn-out provisions tied to Garda's 2025 revenue run rate.

The delay matters because Assertio operates with a constrained balance sheet. The company reported $41 million in cash and equivalents as of September 2024, with $287 million in long-term debt. The Garda acquisition was structured to be funded through a combination of cash on hand and incremental term loan facilities, contingent on lender approval. If the postponement stems from financing friction, Assertio may be forced to revise deal terms or seek alternative capital, which would dilute equity holders or subordinate existing creditors. Alternatively, if the delay reflects Garda's reluctance to proceed at the agreed valuation, Assertio may be negotiating downward or restructuring the consideration mix. The specialty pharma sector has seen 22% compression in EBITDA multiples since mid-2023, driven by heightened scrutiny of opioid-adjacent portfolios and tightening reimbursement across commercial payers.

Operators should monitor two catalysts. First, any amended 13D or SC TO-I filings from Assertio or Garda within the next 30 days, which would reveal revised terms, financing sources, or termination fees. Second, Assertio's Q1 2025 earnings call in early May, where management will face direct questions on the transaction's viability and alternative strategic pathways if the deal collapses. Garda, as a private entity, will remain opaque unless Assertio discloses material changes under Regulation M-A.

The postponement is not termination, but indefinite deferrals in specialty pharma M&A rarely resolve without material repricing. Assertio's stock closed Wednesday at $3.12, down 4.3% on below-average volume, signaling the market is not yet pricing in full deal risk. If the tender offer does not commence by mid-April, allocators should assume the transaction is either restructured or dead.